Permanent cell cycle arrest in asynchronously proliferating normal human fibroblasts treated with doxorubicin or etoposide but not camptothecin

Biochemical Pharmacology

Volumn 58, Issue 4, 1999, Pages 675-685

  Robles, Steven J ^a   Buehler, Paul W ^a   Negrusz, Adam ^a   Adami, Guy R ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Camptothecin; Cell cycle; Cisplatin; Doxorubicin; Etoposide; Fibroblasts

Indexed keywords

CAMPTOTHECIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; PHLEOMYCIN;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE S PHASE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DNA DEGRADATION; DNA STRAND BREAKAGE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SKIN FIBROBLAST;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL CYCLE; CELL DIVISION; CELL SURVIVAL; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DACTINOMYCIN; DNA DAMAGE; DOXORUBICIN; ETOPOSIDE; FIBROBLASTS; HUMANS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033567423     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00127-6     Document Type: Article

References (54)

1. 1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev. 8:1994;2540-2551.
2. Ko L.J., Prives C. p53 Puzzle and paradigm . Genes Dev. 10:1996;1054-1072.
3. Bates S., Vousden K.H. p53 in signaling checkpoint arrest or apoptosis. Curr Opin Genet Dev. 6:1996;12-18.
4. 1 arrest. Proc Natl Acad Sci USA. 93:1996;4827-4832.
5. Xia S.J., Shammas M.A., Reis R.J. Elevated recombination in immortal human cells is mediated by HsRAD51 recombinase. Mol Cell Biol. 17:1997;7151-7158.
6. Linke S.P., Clarkin K.C., Wahl G.M. p53 mediates permanent arrest over multiple cell cycles in response to γ-irradiation. Cancer Res. 57:1997;1171-1179.
7. Allday M.J., Sinclair A., Parker G., Crawford D.H., Farrell P.J. Epstein-Barr virus efficiently immortalizes human B cells without neutralizing the function of p53. EMBO J. 14:1995;1382-1391.
8. 1 arrest is selectively mediated by the p53-WAF1/Cip1 pathway in human thyroid cells. Cancer Res. 55:1995;2075-2080.
9. Lowe S.W., Ruley H.E., Jacks T., Housman D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:1993;957-967.
10. Merritt A.J., Potten C.S., Kemp C.J., Hickman J.A., Balmain A., Lane D.P., Hall P.A. The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res. 54:1994;614-617.
11. Midgley C.A., Owens B., Briscoe C.V., Thomas D.B., Lane D.P., Hall P.A. Coupling between gamma irradiation, p53 induction and the apoptotic response depends upon cell type in vivo. J Cell Sci. 108:1995;1843-1848.
12. Canman C.E., Chen C.Y., Lee M.H., Kastan M.B. DNA damage responses p53 induction, cell cycle perturbations, and apoptosis . Cold Spring Harb Symp Quant Biol. 59:1994;277-286.
13. Nelson W.G., Kastan M.B. DNA strand breaks The DNA template alterations that trigger p53-dependent DNA damage response pathways . Mol Cell Biol. 14:1995;1815-1823.
14. White E. Life, death, and the pursuit of apoptosis. Genes Dev. 10:1996;1-15.
15. Limoli C.L., Kaplan M.I., Phillips J.W., Adair G.M., Morgan W.F. Differential induction of chromosomal instability by DNA strand-breaking agents. Cancer Res. 57:1997;4048-4056.
16. Morgan W.F., Day J.P., Kaplan M.I., McGhee E.M., Limoli C.L. Genomic instability induced by ionizing radiation. Radiat Res. 146:1996;247-258.
17. Chang W.P., Little J.B. Evidence that DNA double-strand breaks initiate the phenotype of delayed reproductive death in Chinese hamster ovary cells. Radiat Res. 131:1992;53-59.
18. Vamvakas S., Vock E.H., Lutz W.K. On the role of DNA double-strand breaks in toxicity and carcinogenesis. Crit Rev Toxicol. 27:1997;155-174.
19. Froelich-Ammon S.J., Osheroff N. Topoisomerase poisons Harnessing the dark side of enzyme mechanism . J Biol Chem. 270:1995;21429-21432.
20. Chen A.Y., Liu L.F. DNA topoisomerases Essential enzymes and lethal targets . Annu Rev Pharmacol Toxicol. 34:1994;191-218.
21. Long B.H., Musial S.T., Brattain M.G. Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide. Cancer Res. 45:1985;3106-3112.
22. Ross W.E., Bradley M.O. DNA double-stranded breaks in mammalian cells after exposure to intercalating agents. Biochim Biophys Acta. 654:1981;129-134.
23. Liu L.F. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem. 58:1989;351-375.
24. Huang C.H., Mirabelli C.K., Jan Y., Crooke S.T. Single-strand and double-strand deoxyribonucleic acid breaks produced by several bleomycin analogues. Biochemistry. 20:1981;233-238.
25. Lazo J.S., Chabner B.A. Bleomycin. Chabner B.A. Cancer Chemotherapy and Biotherapy. 1996;379-393 Lippincott-Raven Publishers, Philadelphia.
26. Reed E., Dabholkar M., Chabner B.A. Platinum analogues. Chabner B.A. Cancer Chemotherapy and Biotherapy. 1996;357-378 Lippincott-Raven Publishers, Philadelphia.
27. Ryan A.J., Squires S., Strutt H.L., Johnson R.T. Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA. Nucleic Acids Res. 19:1991;3295-3300.
28. Hsiang Y.H., Lihou M.G., Liu L.F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 49:1989;5077-5082.
29. INK4a enrichment and the premature senescence of normal fibroblasts. Oncogene. 16:1998;1113-1123.
30. Harper J.W., Adami G.R., Wei N., Keyomarsi K., Elledge S.J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 75:1993;805-816.
31. Gavrieli Y., Sherman Y., Ben-Sasson S.A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 119:1992;493-501.
32. 1 arrest in established human tumor cell lines. Oncogene. 11:1995;1885-1892.
33. Doroshow J.H. Anthracyclines and anthracenediones. Chabner B.A. Cancer Chemotherapy and Biotherapy. 1996;409-432 Lippincott-Raven Publishers, Philadelphia.
34. Myers C. Anthracyclines and DNA intercalators. Holland J.F., Bast R.C. Jr, Morton D.L., Frei E. III, Kufe D.W., Weichselbaum R.R. Cancer Medicine. 1997;977-990 Williams & Wilkins, Philadelphia.
35. Pommier Y., Fesen M.R., Goldwasser F. Topoisomerase II inhibitors The epidophyllotoxins, mAMSA, and the ellipticine derivatives . Chabner B.A. Cancer Chemotherapy and Biotherapy. 1996;435-460 Lippincott-Raven Publishers, Philadelphia.
36. Takimoto C.H., Arbuck S.G. The camptothecins. Chabner B.A. Cancer Chemotherapy and Biotherapy. 1996;463-483 Lippincott-Raven Publishers, Philadelphia.
37. Lu X., Lane D.P. Differential induction of transcriptionally active p53 following UV or ionizing radiation Defects in chromosome instability syndromes? Cell. 75:1993;765-778.
38. Kulkarni G.V., McCulloch C.A. Serum deprivation induces apoptotic cell death in a subset of Balb/c 3T3 fibroblasts. J Cell Sci. 107:1994;1169-1179.
39. Dijt F.J., Fichtinger-Schepman A.M., Berends F., Reedijk J. Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts. Cancer Res. 48:1988;6058-6062.
40. Pera M.F., Rawlings C.J., Roberts J.J. The role of DNA repair in the recovery of human cells from cisplatin toxicity. Chem Biol Interact. 37:1981;245-261.
41. Peterson C., Baurain R., Trouet A. The mechanism for cellular uptake, storage and release of daunorubicin. Studies on fibroblasts in culture. Biochem Pharmacol. 29:1980;1687-1692.
42. 3H-actinomycin D by mammalian cells in vitro. J Pharmacol Exp Ther. 192:1975;270-279.
43. Johnson B.A., Cheang M.S., Goldenberg G.J. Comparison of adriamycin uptake in chick embryo heart and liver cells and murine L5178Y lymphoblasts in vitro Role of drug uptake in cardiotoxicity . Cancer Res. 46:1986;218-223.
44. Kastan M.B., Onyekwere O., Sidransky D., Vogelstein B., Craig R.W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:1991;6304-6311.
45. el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
46. Buehler PW, Robles SJ, Adami GR, Gajee R and Negrusz A, Analysis of doxorubicin in cell culture media and human plasma using solid phase extraction and HPLC. Chromatographia, in press.
47. Stecca C., Gerber G.B. Adaptive response to DNA-damaging agents A review of potential mechanisms . Biochem Pharmacol. 55:1998;941-951.
48. Dimri G.P., Lee X., Basile G., Acosta M., Scott G., Roskelley C., Medrano E.E., Linskens M., Rubelj I., Pereira-Smith O., Campisi J. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA. 92:1995;9363-9367.
49. D'Arpa P., Beardmore C., Liu L.F. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res. 50:1990;6919-6924.
50. Pantazis P., Early J.A., Kozielski A.J., Mendoza J.T., Hinz H.R., Giovanella B.C. Regression of human breast carcinoma tumors in immunodeficient mice treated with 9-nitrocamptothecin Differential response of nontumorigenic and tumorigenic human breast cells in vitro . Cancer Res. 53:1993;1577-1582.
51. Chan K.K., Cohen J.L., Gross J.F., Himmelstein K.J., Bateman J.R., Tsu-Lee Y., Marlis A.S. Prediction of adriamycin disposition in cancer patients using a physiologic, pharmacokinetic model. Cancer Treat Rep. 62:1978;1161-1171.
52. Tattersall M.H.N., Sodergren J.E., Sengupta S.K., Trites D.H., Modest E.J., Frei E. III. Pharmacokinetics of actinomycin D in patients with malignant melanoma. Clin Pharmacol Ther. 17:1975;701-708.
53. Duchaud E., Ridet A., Stoppa-Lyonnet D., Janin N., Moustacchi E., Rosselli F. Deregulated apoptosis in ataxia telangiectasia Association with clinical stigmata and radiosensitivity . Cancer Res. 56:1996;1400-1404.
54. Brunk U.T., Dalen H., Roberg K., Hellquist H.B. Photo-oxidative disruption of lysosomal membranes causes apoptosis of cultured human fibroblasts. Free Radic Biol Med. 23:1997;616-626.